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Molecular imaging with promise of personalized medicine can provide patient-speciﬁc information noninvasively, thus enabling
treatment to be tailored to the speciﬁc biological attributes of both the disease and the patient. This study was to investigate the
characterization of DO3A-CH2CO-G-4-aminobenzoyl-Q-W-A-V-G-H-L-M-NH2 (AMBA) in vitro, MicroSPECT/CT imaging,
and biological activities of 111In-AMBA in PC-3 prostate tumor-bearing SCID mice. The uptake of 111In-AMBA reached highest
with 3.87 ± 0.65%ID/g at 8h. MicroSPECT/CT imaging studies suggested that the uptake of 111In-AMBA was clearly visualized
between 8 and 48h postinjection. The distribution half-life(t1/2α) and the elimination half-life(t1/2β)o f111In-AMBA in mice were
1.53h and 30.7h, respectively. The Cmax and AUC of 111In-AMBA were 7.57%ID/g and 66.39h∗%ID/g, respectively. The eﬀective
dose appeared to be 0.11mSv/MBq−1. We demonstrated a good uptake of 111In-AMBA in the GRPR-overexpressed PC-3 tumor-
bearing SCID mice. 111In-AMBA is a safe, potential molecular image-guided diagnostic agent for human GRPR-positive tumors,
rangingfrom simpleandstraightforwardbiodistribution studies to improve the eﬃcacyof combinedmodalityanticancer therapy.
1.Introduction
Prostate cancer is estimated to rank ﬁrst in number of
cancer cases and second in number of deaths due to
cancer among men in the Western world [1]. Gastrin-
releasing peptides (GRPs), including Bombesin-like peptides
(BLPs), are involved in the regulation of a large number
of biological processes in the gut and central nervous
system (CNS) [2]. They mediate their action on cells by
binding to members of a superfamily of G protein-coupled
receptors [3]. There are four known subtypes of BN-related
peptide receptors, namely, gastrin-releasing peptide receptor
(GRPR, BB2, BRS-2), neuromedin B receptor (NMBR, BB1,
BRS-1), orphan receptor (BRS-3), and amphibian receptor
(BB4-R) [4]. Except the BB4-R, all the receptors were
widely distributed, especially in the gastrointestinal (GI)
tract and central nervous system (CNS). The receptors
have a large range of eﬀects in both normal physiology
and pathophysiological conditions [5]. GRPRs are normally
expressed in nonneuroendocrine tissues of the pancreas,
breast, and neuroendocrine cells of the brain, GI tract, lung,
and prostate, but are not normally expressed by epithelial
cells in the colon, lung, or prostate [6, 7].
Molecular imaging enables the visualization of the
cellular function and the followup of the molecular process
in living organisms without perturbing them [8]. The
radionuclide molecular imaging technique is the most
sensitive and can provide target-speciﬁc information. The
radiotracer could also be used for radionuclide therapy.
Thus, the development of a personalized theranostic (image
and treat) agent would allow greater accuracy in selection
of patients who may respond to treatment, and assessing
the outcome of therapeutic response [9]. Gastrin-releasing
peptide receptors (GRPRs) are overexpressed in several
primary human tumors and metastases [5]. Markwalder and
Reubireported thatGRPRs are expressed in invasive prostate
carcinomas andin prostaticintraepithelial neoplasms athigh2 Journal of Biomedicine and Biotechnology
density, whereas normal prostate tissue and hyperplastic
prostate tissue were predominantly GRPR negative [10].
Theseﬁndings suggestthatGRPRmaybeusedasamolecular
basis for diagnosing and staging prostate cancer, further for
imaging-guided personalized medicine using radiolabeled
bombesin analogues.
Previous studies have evaluated the 111In-radiolabeled
BN analogues which bind rapidly into GRP receptor-
positive tumor cells, including PC-3, CA20948, and
AR42J using gamma camera imaging after administra-
tion [11–14]. AMBA (DO3A-CH2CO-G-(4-aminobenzoyl)-
QWAVGHLM-NH2)( Figure 1), a BBN-related peptide ago-
nist, has a DO3A structure that can chelate tripositive
lanthanide isotopes, such as 68Ga, 90Y, 111In, and 177Lu.
Thus, it can formulate many kinds of radiolabelled probes
for various purposes [15]. Indium 111 emits γ-photons
of two energies (172 and 245keV) as well as Auger and
internal conversion electrons. 111In-AMBA was initially
used for diagnostic purposes but remains the potential for
radiotherapy. Auger electron, with a maximum energy of
<30keV, is a high linear energy transfer (LET) radiation
with subcellular pathlength (2–500nm) in tissues [16]. For
imaging the presence or absence of GRPR, the 111In-AMBA
could be used for patient selection for further radiotherapy
(177Lu-AMBA), chemotherapy (BLP antagonists), or thera-
peutic response monitoring as imaging-guided personalized
medicine. Although 111In-AMBA has been evaluated as an
imaging agent [17–20], the pharmacokinetics and dosimetry
of the agent have not been reported yet. In this study, 111In-
A M B Aw a sd e s i g n e da sa ni m a g e - g u i d e dd i a g n o s t i ca g e n t
for human GRPR-positive tumors, which only retain the last
eight amino acids (Q-W-A-V-G-H-L-M-NH2)f r o mn a t i v e
BN. The pharmacokinetics, biodistribution, dosimetry, and
micro-SPECT/CT imaging of 111In-AMBA were evaluated in
human androgen-independent PC-3 prostate tumor-bearing
SCID mice.
2.Materialsand Methods
2.1. Chemicals. Protected Nα-Fmoc-amino acid derivatives
were purchased from Calbiochem-Novabiochem (Laufel-
ﬁngen,Switzerland),Fmoc-amideresinandcouplingreagent
were purchased from Applied Biosystems Inc. (Foster City,
CA, USA), and DOTA-tetra (tBu) ester was purchased
from Macrocyclics (Dallas, TX, USA). Fmoc-4-abz-OH
was obtained from Bachem (Chauptstrasse, Switzerland).
Bombesin was purchased from Fluka (Buchs, Switzerland).
2.2. Synthesis of AMBA. AMBA was synthesized by
solid phase peptide synthesis (SPPS) using an Applied
Biosystems Model 433A full automated peptide synthesizer
(Applied Biosystems, Foster City, CA, USA) employing the
Fmoc (9-ﬂuorenylmethoxy-carbonyl) strategy. Carboxyl
groups on Fmoc-protected amino acids were activated
by (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium
hexaﬂuorophosphate (HBTU), forming a peptide bond
with the N-terminal amino group on the growing peptide,
anchored via the C-terminus to the resin, provided
for stepwise amino acid addition. Rink Amide resin
(0.25mmole) and Fmoc-protected amino acids (1.0mmoL),
with appropriate side-chain protections, and DOTA-tetra
(tBu ester) were used for SPPS of the BBN conjugates. Side
chain protecting groups in the synthesis were Trt for Gln and
His, and Boc for Trp.
The protected peptide-resin was cleaved and deprotected
with mixture of 50% triﬂuoroacetic acid (TFA): 45%
chloroform, 3.75% anisole, and 1.25% 1, 2-ethanedithiol
(EDT) for 4h at room temperature (RT). The crude peptide
was isolated by precipitating with cool diethyl ether. After
centrifugation, the collected precipitate was dried under
vacuum. The crude peptide sample was puriﬁed by reverse
phase high-performance liquid chromatography (HPLC)
using a column of XTerra prep, MSC18, 5μm, 18 × 50mm
(WatersCorp.,MA,USA)withanacetonitrile/watergradient
consisting of solvent A (0.1% TFA in H2O) and solvent
B (0.1% TFA in acetonitrile), with a 14.8% yield; ﬂow:
6mL/min; gradient: 20%–40% B for 20min. The molecular
weight was determined with a MALDI-TOF Mass Spectrom-
eter (Bruker Daltonics Inc, Germany). M/z determined for
the peptide was AMBA, 1,502.6 [M+H].
2.3. Radiolabeling of 111In-AMBA. AMBA was radiolabeled
with 111In as previously described by Zhang et al. [21].
Brieﬂy, AMBA was labeled with 111In (111InCl3, Institute
of Nuclear Energy Research (INER), Taoyuan (Taiwan),
16430MBq/mL in 0.05NHCl, pH 1.5–1.9) by reaction of
6.66 × 10−4μmole (1μg) peptide in 95μL0 . 1 MN H 4OAc
(pH 5.5) with 64.75MBq 111InCl3 in 5μL 0.04N HCl for
10min at 95◦C. The speciﬁc activity of 111In-AMBA was
9.72 × 104 MBq/μmole. The radiolabeling eﬃciency was
analyzed using instant thin-layer chromatography (ITLC SG,
Pall Corporation, New York. USA) with 0.1M Na-citrate
(pH 5.0) as solvent (indium citrate and 111InCl3:R f= 0.9∼
1.0, peptide-bound 111In: Rf = 0∼0.1) [22]. Radio high-
performance liquid chromatography (Radio-HPLC) analysis
was performed using a Waters 2690 chromatography system
with a 2996 photodiode array detector (PDA), a Bioscan
radiodetector (Washington, DC, USA), and an FC 203B
fraction collector by Gilson (Middleton, WI, USA). 111In-
AMBA was puriﬁed by an Agilent (Santa Clara, CA, USA)
Zorbax bonus-RP HPLC column (4.6 × 250mm, 5μm)
eluted with a gradient mixture from 10% B to 40% B in
40min.Flowratewas1mL/minatRT,andtheretentiontime
for 111In-AMBA was 22.5min. After puriﬁcation by HPLC,
100% ethanol was used instead of acetonitrile by solvent
exchange with Waters Sep-Pak Light C18 cartridge (Milford,
MA, USA). Normal saline was added after evaporation, and
pH value was at the range 7∼7.5.
2.4. Receptor Cold Competition Assay. Cold competition
binding assay was studied using human bombesin 2 receptor
expressed in HEK-293 cells as the source of GRP receptors
(PerkinElmer, Boston, MA, USA). Assays were performed
using FC96 plates and the Multiscreen system (Millipore,
Bedford, MA). Bindingof 125I-Tyr4-Bombesin (PerkinElmer,Journal of Biomedicine and Biotechnology 3
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Figure 1: Representative structure of AMBA.
Boston, MA, USA) to human bombesin 2 receptor (0.16μg
per well) was determined in the presence of increasing
concentrations (0.001nmole/L to 1000nmole/L) of unla-
beled AMBA in a buﬀer solution (20mmol/L HEPES, pH
7.4, 3mmol/L MgCl2, 1mmol/L EDTA, and 0.3% BSA)
with a total volume of 250μL per well. After incubation
for 60min at RT, membranes were ﬁltered and washed with
ice-cold Tris-HCl buﬀer (50mmol/L). The ﬁlters containing
membrane-bound radioactivity were counted using a Cobra
II gamma-counter (Packard, Meriden, CT). The inhibitory
concentration of 50% (IC50) was calculated using a four-
parameter curve-ﬁtting routine using the KELL software for
Windows version 6 (Biosoft, Ferguson, MO, USA) [13].
2.5. Cell Culture and Animal Model. Human androgen-
independent prostate cancer PC-3 cells (Bioresource Collec-
tion and Research Center, Taiwan) were cultured in Ham’s F-
12K medium supplemented with 10% heat-inactivated fetal
bovineserum(allfromGIBCO,GrandIsland,NY,USA)con-
taining 5% CO2 at 37◦C. For animal inoculation, an aliquot
was thawed, grown and used within 10 passages. Five-week-
old male ICR SCID (severely compromised immunodeﬁ-
cient)outbredmice were obtained fromthe NationalAnimal
Center of Taiwan (Taipei, Taiwan, ROC) and maintained on
a standard diet (Lab diet; PMI Feeds, St. Louis, MO, USA)
at RT, with free access to tap water in the animal house
of INER). Thirty-three SCID mice were subcutaneously
injected with 2 × 106 PC-3 cells in the right hind ﬂank.
The animal experiments were approved by the Institutional
Animal Care and Use Committee (IACUC) of the INER.
2.6. Biodistribution Studies. At 4 weeks after PC-3 cell
inoculation,theweightofthedevelopedtumorsranged from
0.05 to 0.2g. Twenty-ﬁve PC-3 xenograft SCID mice (n =
5 for each group) were injected with 0.37MBq (0.1μg) of
the 111In-AMBA in 100-μL normal saline via the tail vein.
T h em i c ew e r es a c r i ﬁ c e db yC O 2 asphyxiation with tissues
and organs excised at 1, 4, 8, 24, and 48h postinjection
(p.i.). Subsequently, the tissues and organs were weighed,
radioactivity was counted in a Packard Cobra II gamma-
counter by Perkin-Elmer (Waltham, MA, USA), and the
percentageofinjecteddosepergram(%ID/g)foreachorgan
or tissue was calculated [23].
2.7. Pharmacokinetic Studies. Six PC-3 xenograft SCID mice
were injected with 0.37MBq (0.1μg) of the 111In-AMBA in
100-μL normal saline via the tail vein. At 0.25, 1, 4, 16,
24, 48, 72, 96, and 168h p.i., 20μL of blood was collected
from the heart puncture, then the blood was weighed,
radioactivity was counted in the Cobra II gamma-counter,
and the percentage of injected dose per gram (%ID/g) was
calculated.Thedatawereﬁttedtoatwo-compartment model
and the pharmacokinetic parameters were derived by the
WinNonlin 5.0 software (Pharsight Corporation, Mountain
View, CA, USA).
2.8. Micro-SPECT/CT Imaging. T w om a l eS C I Dm i c eb e a r -
ing human PC-3 tumors of approximately 0.1g were i.v.
injected with 12.2MBq/4μg 111In-AMBA after puriﬁcation
by radio-HPLC. The SPECT and CT images were acquired
by a micro-SPECT/CT scanner system (XSPECT; Gamma
Medica-ideas Inc., Northridge, CA, USA). SPECT imaging
was performed using medium-energy, parallel-hole colli-
mators at 1, 4, 8, 24, and 48h. The source and detector
were mounted on a circular gantry allowing them to rotate
360 degrees around the subject (mouse) positioned on a
stationary bed. The ﬁeld of view (FOV) was 12.5cm. The
imaging acquisition was accomplished using 64 projections
at 90 seconds per projection. The energy windows were set
at 173keV ± 10% and 247keV ± 10%. SPECT imaging was
followed by CT imaging (X-ray source: 50kV, 0.4mA; 256
projections) with the animal in exactly the same position. A
three-dimensional (3D) Feldkamp cone beam algorithm was
used for CT image reconstruction, and a two-dimensional
(2D) ﬁltered back projection algorithm was used for
SPECT image reconstruction. All image processing soft-
wares, including SPECT/CT coregistration, were provided
by Gamma Medica-Ideas Inc (Northridge, CA, USA). After
coregistration, boththefused SPECTandCTimageshad256
× 256 × 256 voxels with an isotropic 0.3-mm voxel size.
2.9. Absorbed Radiation Dose Calculations. The relative
organ mass scaling method was employed to extrapolate
the animal data to humans [24, 25]. The mean absorbed
dose in various tissues was calculated from the radionuclide
concentration in tissues/organs of interest, assuming a
homogeneous distribution of the radionuclide within any
source region [26]. The calculated mean value of percentage4 Journal of Biomedicine and Biotechnology
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Figure 2: Competitive binding assay of AMBA versus 125I-Tyr4-
Bombesin with human bombesin 2 receptors.
of injected activity per g (%IA/g) for the organs in mice was
extrapolated to uptake in organs of a 70-kg adult using the
following formula [24]:
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The extrapolated values (%IA) in the human organs at 1, 4,
8,24,and48hwereﬁttedwithexponentialbiokineticmodels
and integrated to obtain the number of disintegrations in
the source organs. This information was entered into the
OLINDA/EXM computer program. The integrals (MBq-s)
for 15 organs, including heart contents (blood), brain, mus-
cle, bone, heart, lung, spleen, pancreas, kidneys, liver, and
remainder of body were evaluated and used for dosimetry
evaluation. The code also displays contributions of diﬀerent
source organs to the total dose of target organs. For the
estimation of the tumor absorbed dose, it was assumed that
once the radiopharmaceutical is inside the tumor, there is no
biological elimination.
3.Results
3.1. Radiolabeling and In Vitro Receptor Binding Assay.
The radiolabeling eﬃciency of 111In-AMBA was 95.43 ±
1.37% (n = 11). The in vitro competitive binding assays
were determined in the human bombesin 2 receptor using
125I-Tyr4-Bombesin as the GRP-R speciﬁc radiotracer, and
unlabeled AMBA and native BN as competitors. The IC50
of the AMBA and native BN in human bombesin 2 receptor
(Figure 2)i s0 .82 ± 0.41nmol/L and 0.13 ± 0.10nmol/L,
respectively, in a single, direct, nanomolar range, demon-
strating high speciﬁcity and aﬃnity for the GRP receptor.
The Ki of AMBA and native BBN were 0.65 ± 0.32nmol/L
and 0.10 ± 0.08nmol/L, respectively.
3.2. Biodistribution. 111In-AMBA accumulated signiﬁcantly
in tumor, adrenal, pancreas, small intestine, and large
intestine (Table 1). Fast blood clearance and fast excretion
from the kidneys were observed. High levels of radioactivity
were found in the kidneys before 24h, indicating that the
radioactivity was excreted rapidly in the urine within 24h.
The levels of radioactivity reached the highest with 3.87 ±
0.65%ID/g at 8h and then declined rapidly. The highest
tumor/muscle ratio (Tu/Mu) of 111In-AMBA was 11.79 at
8h after injection and decreased progressively to 4.82 and
5.16 at 24 and 48h after administration, respectively. Other
GRPR-positive organs (small intestine and large intestine)
also showed the speciﬁc binding of 111In-AMBA (Table 1).
The tumor/muscle ratios were decreased conspicuously at 4
and 24h postadministration.
3.3. Pharmacokinetic Studies. The radioactivity declined
to under detection limit after 24h. The pharmacokinetic
parameters derived by a two-compartment model [27]i n d i -
cated that the distribution half-life (t1/2α)a n dd i s t r i b u t i o n
half-life(t1/2β)of111In-AMBAwere1.53 ±0.69hand30.73±
8.56h, respectively (Table 2).
3.4. Micro-SPECT/CT Imaging. Micro-SPECT/CT imaging
of 111In-AMBA indicated signiﬁcant uptake in the tumors at
8 and 24h after intravenous injection (Figure 3). The longi-
tudinal micro-SPECT/CT imaging showed high accumula-
tion of 111In-AMBA in pancreas and gastrointestinaltract at
4, 8, 24, and 48h after intravenous injection.
3.5. Radiation Absorbed Dose Calculation. The radiation-
absorbed dose projections for the administration of 111In-
AMBA to humans, determined from the residence times
in mice, are shown in Table 3. The highest absorbed doses
appear in the lower large intestine (0.12mSv/MBq−1),
upper large intestine (0.13mSv/MBq−1), kidneys
(0.12mSv/MBq−1), osteogenic cells (0.22mSv/MBq−1),
and pancreas (0.25mSv/MBq−1). The eﬀective dose appears
to be approximately m0.11mSv/MBq−1. The red marrow
absorbed dose is estimated to be 0.09mSv/MBq−1.F o ra
2-g tumor, the unit density sphere model was used and the
estimated absorbed dose was 8.09mGy·MBq−1.
4.Discussion
Growth factor receptors are involved in all steps of tumor
progression, enhancing angiogenesis, local invasion, and
distant metastases. The overexpression of growth factor
receptors on the cell surface of malignant cells might be
associated with a more aggressive behavior and a poor
prognosis. For these reasons, tumor-related growth factor
receptors can be taken as potential targets for therapeutic
intervention. Overthe last two decades, GRP and other BLPs
may act as a growth factor in many types of cancer. GRPR
antagonists have been developed as anticancer candidateJournal of Biomedicine and Biotechnology 5
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Figure 3: MicroSPECT/CT images of 111In-AMBA targeting PC-3 tumors xenograft SCID mice. 12.2 MBq/4μg 111In-AMBA was
administered to each mouse by intravenous injection. The images were acquired at 1, 4, 8, 24, and 48h after injection. The energy window
was set at 173keV ± 10% and 247keV ±10%; the image size was set at 80 × 80 pixels. The color map shows the SPECT pixel values from 0
to the maximum expressed with an arbitrary value of 100.
Table 1: Biodistribution of 111In-AMBA after intravenous injection in PC-3 prostate tumor-bearing SCID mice.
Organ 1h 4h 8h 24h 48h
Blood 0.95 ±0.09 0.50 ±0.06 0.42 ± 0.02 0.19 ±0.03 0.09 ± 0.02
Brain 0.06 ±0.01 0.05 ±0.01 0.05 ± 0.00 0.02 ±0.00 0.03 ± 0.00
Skin 0.99 ±0.22 0.60 ±0.16 0.55 ± 0.02 0.36 ±0.02 0.28 ± 0.02
Muscle 0.57 ±0.19 0.33 ±0.14 0.33 ± 0.02 0.21 ±0.04 0.14 ±0.02
Bone 1.02 ±0.18 0.92 ±0.21 1.57 ± 0.18 0.90 ±0.13 0.60 ± 0.07
Heart 0.62 ±0.09 0.48 ±0.04 0.56 ± 0.08 0.41 ±0.05 0.32 ± 0.04
Lung 1.78 ± 0.23 1.88 ±0.46 1.70 ± 0.65 0.60 ± 0.17 0.26 ± 0.03
Adrenals 5.79 ±1.21 7.08 ±1.22 17.8 ± 4.65 7.41 ±1.99 5.20 ± 1.11
Spleen 2.80 ±1.49 6.90 ±1.87 8.90 ± 2.34 4.41 ±0.58 2.19 ± 0.51
Pancreas 6.14 ±0.99 12.9 ±2.44 54.9 ± 2.51 15.9 ±1.94 9.80 ± 2.21
Kidney 3.56 ±0.15 4.23 ±0.28 3.92 ± 0.91 4.10 ±0.72 2.74 ±0.30
Liver 7.26 ±0.53 8.22 ±1.05 7.04 ± 0.24 8.64 ±1.31 6.59 ± 1.83
Bladder 7.63 ±2.94 1.75 ±0.75 1.07 ± 0.12 0.64 ±0.06 0.46 ±0.10
Stomach 0.81 ±0.09 0.80 ±0.07 3.97 ± 1.15 0.97 ±0.29 0.47 ± 0.05
SI 1.67 ±0.22 1.56 ±0.17 4.42 ± 0.61 1.48 ±0.27 0.74 ± 0.10
LI 1.77 ±0.25 3.42 ±1.10 7.04 ± 1.48 2.39 ±0.38 0.99 ± 0.16
Tumor (PC-3) 2.24 ±0.66 1.86 ±0.71 3.87 ± 0.65 1.02 ±0.09 0.75 ±0.08
Tumor/muscle 3.89 5.69 11.79 4.82 5.16
Values are expressed as %ID/g, mean ± SEM (n = 4-5 at each time point). SI: small intestine; LI: large intestine.
compounds, exhibiting impressive antitumoral activity both
in vitro and in vivo in various murine and human tumors
[28, 29]. Clinical trials with GRPR antagonists in cancer
patients are in its initial phase as anticipated by animal
toxicology studies and preliminary evaluation in humans
[29]. Presently, eﬀorts at the identiﬁcation of the most
suitable candidates for clinical trials and at improving drug
formulation for human use are considered priorities. It
may also be anticipated that GRPRs may be exploited as
potential carriers for cytotoxins, immunotoxins, or radioac-
tive compounds. Thus, the visualization of these receptors
through molecular image-guided diagnostic agents may
become an interesting tool for tumor detection and staging
in personalized medicine.
The present study showed the highest accumulation
of 111I n - A M B Ai np a n c r e a si nm i c e( Table 1). However,
interspecies diﬀerences in structure and pharmacology of
human and animal GRP receptors have been reported [30].6 Journal of Biomedicine and Biotechnology
Table 2: Pharmacokinetic parameters of plasma in PC-3 tumor-
bearing mice after intravenous injection of 10μCi/mouse 111In-
AMBA (mean ± SEM, n = 5).
Parameter Unit Value
A% I D / g 6 .15 ±0.69
B% I D / g 1 .43 ±0.61
α 1/h 1.19 ±0.85
β 1/h 0.03 ±0.01
AUC0−168h h × (%ID/g) 66.4 ±17.3
t1/2α h1 .53 ±0.69
t1/2β h3 0 .7 ±8.56
Cmax %ID/g 7.37 ±0.64
A, B, α, β: macro rate constants; t1/2α, t1/2β: distribution and elimination
half-lives; AUC0−168h: area under concentration of 111In-AMBA versus
time curve; Cmax: maximumconcentration in plasma.
Table 3: Radiation dose estimates for 111In-AMBA in humans.
Organ Estimated dose (mSv/MBq−1)∗
Adrenals 1.5E −01
Brain 3.1E −02
Breasts 7.7E −02
Gallbladder Wall 1.5E −01
LLI Wall 1.2E −01
Small Intestine 1.3E −01
Stomach Wall 1.1E −01
ULI Wall 1.3E −01
Heart Wall 7.2E −02
Kidneys 1.2E −01
Liver 2.0E −01
Lungs 7.4E −02
Muscle 7.0E −02
Ovaries 1.2E −01
Pancreas 2.5E −01
Red Marrow 8.8E −02
Osteogenic Cells 2.2E −01
Skin 5.8E −02
Spleen 1.2E −01
Testes 5.9E −02
Thymus 9.0E −02
Thyroid 9.2E −02
Urinary Bladder Wall 1.1E −01
Uterus 1.3E −01
Total Body 9.2E −02
Eﬀective Dose 1.1E −01
∗Radiation-absorbed dose projections in humans were determined from
residence times for 111In-AMBA in SCID mice and were calculated by use
of OLINDA/EXM version 1.0 computer program.
Because the pancreas is the primary normal tissue in
these animals that expresses a high density of bloodstream-
accessible GRPRs, the accumulation of 111In in the pancreas
isadirectreﬂectionoftheeﬃcacyofradiolabeledBNanalogs
for in vivo targeting of cell-surface-expressed GRPRs [31].
Retention of 111In-AMBA in the pancreas may be due to the
characteristic of a radioagonist with eﬀective internalization
and cell retention. Waser et al. reported that in contrast
to the strongly labeled GRPR-positive mouse pancreas with
177Lu-AMBA,thehumanpancreasdidnotbind 177Lu-AMBA
unless chronic pancreatitis was diagnosed [32].
The majority of research eﬀorts into the design of
bombesin-based radiopharmaceuticalshavebeencarried out
using GRPR agonists. The main reason for using agonists is
that they undergo receptor-mediated endocytosis enabling
residualizationoftheattachedradiometalwithinthetargeted
cell[33].Micro-SPECT/CTimagingisanoninvasiveimaging
modality that can longitudinally monitor the behavior of
G R P Re x p r e s s i o ni nt h es a m ea n i m a la c r o s sd i ﬀerent time-
pointsbeforeandduringtherapy.Inthepresentstudy,tumor
targeting and localization of 111In-AMBA was clearly imaged
with micro-SPECT/CT after 1 to 48h of administration,
suggesting that micro-SPECT/CT imaging with 111In-AMBA
is a good tool for studying the tumor targeting, distribution,
and real-time therapeutic response in vivo.
The eﬀective dose projected for the administration of
111In-AMBAto humans(0.11mSv/MBq−1)(Table 3)isc om -
parable to that for 111In-pentetreotide (0.12mSv/MBq−1)
[34], the only 111In-labeled peptide receptor-targeted radio-
therapeutic agent to be used clinically [35, 36]. The
intestines, osteogenic cells, kidneys, and pancreas appear
to receive absorbed doses around 0.2mSv/MBq−1 of 111In-
AMBA. At a maximum planned administration of 111MBq
for diagnostic imaging, the total radiation-absorbed dose to
these organs kidneys would be about 12mSv. The use of
animal data to estimate human doses is a necessary ﬁrst
step, but such studies give only an estimate of radiation
doses to be expected in human subjects. More accurate
human dosimetry must be established with imaging studies
involving human volunteers or patients. The dosimetry data
presented here will be valuable in the dose planning of these
studies, andforapplicationof 111In-AMBAtoInvestigational
New Drug (IND) research.
Clinically, primary prostate cancer and the metastases
may be heterogeneous, demonstrating a spectrum of phe-
notypes from androgen-sensitive to androgen-insensitive.
177Lu-AMBA, a conjugated bombesin compound for imag-
ing and systemic radiotherapy, is now in phase I clini-
cal trials [15]. 177Lu-AMBA has been evaluated in early
stages of prostate cancer represented by the androgen-
dependent, prostate-speciﬁc antigen-secreting hormone-
sensitive prostate cancer cell line LNCaP [6], derived from
a lymph node metastasis, and also in PC-3 cell line,
derived from bone metastasis, is androgen-independent
and is thought to represent late-stage hormone-refractory
prostate cancer (HRPC) [37]. 177Lu-AMBA will be clinically
eﬃcacious as a single-agent radiotherapeutic for heteroge-
neous metastatic prostate cancer and be a valuable adjunct
to traditional chemotherapy. Thus, the visualization of
GRPR receptors through 111In-AMBA as an image-guided
agent may contribute to the use of radiotherapeutic, 177Lu-
AMBA, and other traditional chemotherapy in personalized
medicine.
Targeted therapeutic and imaging agents are becoming
more prevalent and are used to treat increasingly smallerJournal of Biomedicine and Biotechnology 7
population of patients. This has led to dramatic increases in
the costs for clinical trials. Biomarkers have great potential
to reduce the numbers of patients needed to test novel
targeted agents by predicting or identifying nonresponse
early on and thus enriching the clinical trial population with
patients more likely to respond. GRPRs are expressed on
prostate tumor cells, making it a potential biomarker for
cancer. The imaging of 111In-AMBA indicated the stage of
prostate cancer for determining the therapeutic approach to
prostate cancer and for monitoring the therapeutic eﬃcacy.
The expression of GRPR will vary from patient to patient
due to the stages and individual diﬀerence. If such patients
couldbeprescreenedwith 111In-AMBAto identifythose with
higher tumor expression of GRPR, then it would be possible
to select cases for receiving BLPs-speciﬁc treatment, while
cases with low tumor expression of GRPR can consider other
treatment options. Consequently, the proposed approaches
enableoptimizedandindividualizedtreatmentprotocolsand
can enhance the development of image-guide personalized
medicine.
By visualizing how well drug targeting systems deliver
pharmacologically active agents to the pathological site,
111In-AMBAfurthermore facilitates“personalized medicine”
and patient individualization, as well as the eﬃcacy of
combination regimens. Regarding personalized medicine, it
can be reasoned that only in patients showing high levels
of target site uptake with high expression of GRPR should
treatment be continued; otherwise, alternative therapeutic
approaches should be considered.
5.Conclusion
111In-AMBA showed a characteristic of agonist, a good
bioactivity in vitro and uptake in human GRPR-expressing
tumors in vivo. The molecular image-guided diagnostic
agent can be used for various diﬀerent purposes, ranging
from simple and straightforward biodistribution studies to
extensiveandelaborateexperimental setupsaiming toenable
“personalized medicine” and to improve the eﬃcacy of
combined modality anticancer therapy.
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